Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
topic_facet:"Lung Neoplasms"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=6
/vufind/Search/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=6
Search /vufind/Search2/Results?filter%5B%5D=topic_facet%3A%22Lung+Neoplasms%22&lookfor=%22ClinicalTrials.gov%22&type=JournalTitle&page=6
PubPharm (6.438)
51
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients : A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
52
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer : Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
53
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) : A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants With Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
54
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) : A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
55
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors : Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
56
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC : A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
57
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy : A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy (HERTHENA-Lung02)
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
58
Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations : A Phase 1b Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Antitumor Activity of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
59
Oral Iloprost for the Prevention of Lung Cancer In Former Smokers : Phase II Trial of Oral Iloprost for the Precision Chemoprevention of Lung Cancer
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
60
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors : Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[644]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Lung Neoplasms
Medienart
6.438
Aufsätze
6.438
E-Artikel
6.438
E-Ressourcen
Zeitschriftentitel
6.438
ClinicalTrials.gov
Thema
6.438
610
Lung Neoplasms
5.162
Study Type: Interventional
3.618
Carcinoma, Non-Small-Cell Lung
2.315
Recruitment Status: Completed
1.970
Phase: Phase 2
1.574
Recruitment Status: Recruiting
1.212
Study Type: Observational
778
Phase: Phase 1
737
Small Cell Lung Carcinoma
696
Recruitment Status: Terminated
655
Phase: Phase 3
653
Medical Condition: Lung Cancer
640
Recruitment Status: Active, not recruiting
529
Recruitment Status: Unknown status
429
Carcinoma
396
Recruitment Status: Not yet recruiting
349
Medical Condition: Non-small Cell Lung Cancer
291
Phase: Phase 1, Phase 2
281
Medical Condition: Non Small Cell Lung Cancer
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
3.936
2020-
2.387
2010-2019
115
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
6.438
Englisch
Haven't found what you're looking for?
Wird geladen...